Phase 2, randomised, placebo-controlled trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in subjects with overweight or obesity: a 24-week interim analysis

被引：0
|
作者：
Aronne, L. [1 ]
Harris, M. S. [2 ]
Roberts, M. S. [2 ]
Suschak, J. [2 ]
Tomah, S. [2 ]
He, L. [2 ]
Yang, J. [2 ]
Frias, J. P. [3 ]
Browne, S. K. [2 ]
机构：
[1] Weill Cornell Med, New York, NY USA
[2] Altimmune Inc, Gaithersburg, MD USA
[3] Veloc Clin Res, Los Angeles, CA USA
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
60
引用
收藏
页码：S33 / S34
页数：2
相关论文
共 50 条
  • [31] Does a GLP-1 receptor agonist change glucose tolerance in patients treated with antipsychotic medications? Design of a randomised, double-blinded, placebo-controlled clinical trial
    Larsen, Julie Rask
    Vedtofte, Louise
    Holst, Jens Juul
    Oturai, Peter
    Kjaer, Andreas
    Corell, Christoph U.
    Vilsboll, Tina
    Fink-Jensen, Anders
    BMJ OPEN, 2014, 4 (03):
  • [32] The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients
    Smits, Mark M.
    Tonneijck, Lennart
    Muskiet, Marcel H. A.
    Hoekstra, Trynke
    Kramer, Mark H. H.
    Diamant, Michaela
    van Raalte, Daniel H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 124 : 1 - 10
  • [33] Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial
    Yan, Xiang
    Ma, Jianhua
    Liu, Yan
    Wang, Xuhong
    Li, Sheli
    Yan, Shuang
    Mo, Zhaohui
    Zhu, Yikun
    Lin, Jingna
    Liu, Jie
    Jia, Ying
    Liu, Li
    Ding, Ke
    Xu, Michael
    Zhou, Zhiguang
    LANCET REGIONAL HEALTH-WESTERN PACIFIC, 2024, 47
  • [34] Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
    Nauck, Michael A.
    Stewart, Murray W.
    Perkins, Christopher
    Jones-Leone, Angela
    Yang, Fred
    Perry, Caroline
    Reinhardt, Rickey R.
    Rendell, Marc
    DIABETOLOGIA, 2016, 59 (02) : 266 - 274
  • [35] Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
    Michael A. Nauck
    Murray W. Stewart
    Christopher Perkins
    Angela Jones-Leone
    Fred Yang
    Caroline Perry
    Rickey R. Reinhardt
    Marc Rendell
    Diabetologia, 2016, 59 : 266 - 274
  • [36] Metabolic effects of dapagliflozin QD and exenatide QW in obese adults without diabetes: a 24-week randomised placebo-controlled phase 2 study
    Lundkvist, P.
    Amini, S.
    Borjesson, J. Lau
    Pereira, M.
    Kamble, P.
    Sjostrom, C.
    Johnsson, E.
    Eriksson, J.
    DIABETOLOGIA, 2016, 59 : S377 - S378
  • [37] Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial
    Jensen, Simon Birk Kjaer
    Blond, Martin Baek
    Sandsdal, Rasmus Michael
    Olsen, Lisa Moller
    Juhl, Christian Rimer
    Lundgren, Julie Rehne
    Janus, Charlotte
    Stallknecht, Bente Merete
    Holst, Jens Juul
    Madsbad, Sten
    Torekov, Signe Sorensen
    ECLINICALMEDICINE, 2024, 69
  • [38] Does glucagon-like peptide-1 (GLP-1) receptor agonist stimulation reduce alcohol intake in patients with alcohol dependence: study protocol of a randomised, double-blinded, placebo-controlled clinical trial
    Antonsen, Kerstin K.
    Klausen, Mette K.
    Brunchmann, Amanda S.
    le Dous, Nina
    Jensen, Mathias E.
    Miskowiak, Kamilla Woznica
    Fisher, Patrick M.
    Thomsen, Gerda K.
    Rindom, Henrik
    Fahmy, Thomas P.
    Vollstaedt-Klein, Sabine
    Benveniste, Helene
    Volkow, Nora D.
    Becker, Ulrik
    Ekstrom, Claus
    Knudsen, Gitte Moos
    Vilsboll, Tina
    Fink-Jensen, Anders
    BMJ OPEN, 2018, 8 (07):
  • [39] Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial
    Ishoy, Pelle L.
    Knop, Filip K.
    Broberg, Brian V.
    Bak, Nikolaj
    Andersen, Ulrik B.
    Jorgensen, Niklas R.
    Holst, Jens J.
    Glenthoj, Birte Y.
    Ebdrup, Bjorn H.
    DIABETES OBESITY & METABOLISM, 2017, 19 (02): : 162 - 171
  • [40] The efficacy and safety of tesofensine for weight loss in obese subjects. A 24-week randomised, double-blind, placebo-controlled Danish multi-centre trial
    Astrup, A.
    Madsbad, S.
    Breum, L.
    Kroustrup, J. P.
    Jensen, T. J.
    Larsen, T. M.
    INTERNATIONAL JOURNAL OF OBESITY, 2008, 32 : S23 - S23
12345